Impella CP® in Myocardial Infarction with Cardiogenic Shock: First Evidence in Over 20 Years
This international, multicenter clinical trial (DanGer study) evaluates the effects of routine implantation of the microaxial flow pump (Impella CP®) compared to conventional treatment in patients with acute myocardial infarction complicated by cardiogenic shock.
Better Outcomes of Surgical Aortic Valve Replacement Versus TAVI in Low-Risk Patients in the AVALON Registry: Continuation or Conclusion?
Five-year results from the AVALON registry on percutaneous versus surgical treatment of aortic stenosis in low-risk patients, compared to updated evidence from key clinical trials for the same patient profile.
Advanced therapies for heart failure: heart transplantation vs. LVAD. How to choose? Expert opinion
An expert commentary by Dra. Sonia Mirabet about choices for advanced heart failure therapies.
Berlin Heart® as a bridge to recovery
A systematic review analyzing nearly 1000 pediatric Berlin Heart® implants to describe the characteristics of patients who achieved successful explantation.
Surgical Risk Assessment in Aortic Dissection: The New German Tool
Validation of the perioperative risk prediction system for patients undergoing type A aortic dissection repair derived from the GERAADA German registry.
Cardiac Surgery Following TAVI: Confirming Concerning Outcomes
A retrospective analysis was conducted to evaluate the evolution and outcomes of cardiac surgery in patients with prior TAVI, utilizing data from the STS database from 2012 to 2023.
A review of myocardial protection in cardiac surgery: a retrospective since 2020
This literature review revisits the pathophysiological principles of ischemia, reperfusion, and myocardial ischemia tolerance, as well as the concepts of myocardial protectioN and the main evidence on outcomes among different cardioplegia solutions retrospectively since 2020.
PARTNER 3 at 5 Years: Low-Risk Patients and TAVI… Quo Vadimus?
Five-year results from the PARTNER 3 trial, which evaluated the balloon-expandable SAPIEN 3® TAVI versus surgical aortic valve replacement (SAVR) in low-risk patients.
